P/E ratio for Ocular Therapeutix (OCUL)
P/E ratio as of April 2024 (TTM): -4.09
According to Ocular Therapeutix's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.09052. At the end of 2022 the company had a P/E ratio of -3.09.
P/E ratio history for Ocular Therapeutix from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -3.09 | -96.01% |
| 2021 | -77.4 | 816.61% |
| 2020 | -8.45 | 308.55% |
| 2019 | -2.07 | -18.42% |
| 2018 | -2.54 | 25.33% |
| 2017 | -2.02 | -56.26% |
| 2016 | -4.62 | -16.1% |
| 2015 | -5.51 | 26.55% |
| 2014 | -4.36 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 SurModics SRDX | -15.9 | 287.89% | 🇺🇸 USA |
 Anika Therapeutics ANIK | -16.7 | 308.24% | 🇺🇸 USA |
 Intersect ENT XENT | -12.7 | 210.98% | 🇺🇸 USA |
 Haemonetics HAE | 36.0 | -980.23% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.